Sanjiv.Parant. — 360° view

Sanjiv.Parant, a company in the Pharmaceuticals industry, reported revenue of ₹25 crore and net profit of ₹4.15 crore for the September 2026 quarter.

Sanjiv.Parant. (BSE: SANJIVIN) closed at ₹166.65 on 20 Nov 2026, down 10.1% over the past year. Its market capitalisation is ₹205 crore and it trades at 20.5 times earnings.

Share price
₹166.65 (20 Nov 2026)
Market cap
₹205 Cr (20 Nov 2026)
P/E
20.53 (20 Nov 2026)
Revenue
₹25 Cr (September 2026 quarter)
Net profit
₹4 Cr (September 2026 quarter)
ROCE
18.0% (FY26)
ROE
15.7% (FY26)
Book value
₹44.0 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹244.00 / ₹126.00 (20 Nov 2026)
1-year return
-10.1% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: SANJIVIN

Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.